Anti-Tumor Killer T Cells Are Generated

 

Understanding the steps involved in development of T cells that can specifically target tumor cells and kill them is central to developing drugs that are effective in enhancing anti-tumor immunity.  Here we provide a brief summary of the key stages involved in this process.

Briefly, small fragments derived from tumor cells (antigens) travel through the lymphatic system to the lymph node.  The lymph node is the location where tumor specific killer T cells (CD8, Cytotoxic T cells) are generated.  Specialized cells in the lymph node (dendritic cells) internalize the antigen, then help select and amplify killer T cell populations that are specific to the tumor antigen.  Once the killer T cells have been selected and expanded, they exit the lymph node and return to the tumor, where they can ‘recognize’ and kill the tumor cell.

Central Themes:

  1. How small tumor particles (antigens) travel to the lymph node
  2. The role of specialized cells (dendritic cells) in the lymph node internalize the tumor antigens and find killer T cells that get activated by the antigen.
  3. Steps in generation of tumor antigen-specific killer T cells
  4. Fate of killer T cells after antigen encounter
  5. Trafficking from the lymph node to the tumor
  6. Tumor recognition and killing

1. Tumor Antigen Entry into the Lymph Node

  • Tumor antigens come from dying cancer cells. Some are carried to lymph nodes by special immune cells called dendritic cells. Others flow directly into the lymph node.
  • Tumor antigens are released from dying cancer cells within the tumor. These antigens are transported to the draining lymph node primarily via lymphatic vessels though two different mechanisms. (1) In the first mechanism, specialized cells circulating in the blood (dendritic cells), internalize tumor antigens and migrate to the lymph node. (2) In the second mechanism, soluble antigens can drain directly into the lymph node and be captured and internalized by dendritic cells present in the lymph node.

2. The Role of Dendritic Cells in Generating Tumor Specific Killer T cells

  • Dendritic cells in the lymph node start the process that makes T cells that can attack tumors.
  • Dendritic cells are the main cell type to help preferential expansion of tumor antigen specific T cells. There are two main types of dendritic cells in the lymph node, conventional and follicular. Conventional dendritic cells help make killer T cells and follicular dendritic cells are specialized for facilitating tumor specific antibody production.  Follicular dendritic cells can also assist in T cell development by trapping and retaining tumor antigens, indirectly influencing the activation of killer T cells by modulating the availability of antigens and other factors..

3. Steps in Generation of Tumor Antigen-Specific Killer T Cells

  • First, dendritic cells in the lymph node show tumor antigens to T cells. Then, T cells recognize these antigens and get activated by extra signals. Finally, these T cells multiply and turn into specialized cells that can fight cancer.
  • Step 1. Antigen Capture and Migration. In the lymph node, dendritic cells internalize and then express antigens on their cell surface receptors called Major Histocompatibility Complex (MHC) proteins.
  • Step 2. T Cell Priming and Activation. Naive killer T cells enter the lymph node. Naïve T cells in the circulation have pre-existing T cell receptors, that are specific for a selected antigen. T cells scan dendritic cells for matching antigen-MHC complexes in the lymph node. Upon recognition, T cells receive three signals that determine their fate.
  • Step 3. Clonal Expansion and Differentiation. Activated T cells proliferate and differentiate into tumor specific killer cells and memory T cells.

4. Fate of Killer T Cells After Antigen Encounter

  • Activated killer T cells leave the lymph node, travel to the tumor, and kill cancer cells. Some T cells become memory cells for long-term protection.
  • Killer T Cells: After activation, killer T cells exit the lymph node, enter the circulation, and home to the tumor site.  They mediate direct cytotoxicity against tumor cells expressing the matching antigen.
  • Memory T cells: A fraction of activated T cells become long-lived memory cells, providing durable antitumor immunity.

5. Trafficking from the Lymph Node to the Tumor

Activated T cells change so they can leave the lymph node and enter the bloodstream. In the blood, they find the tumor by following chemical signals. They slow down, stick to blood vessel walls, and move into the tumor.

Step 1. Egress from the Lymph Node. Once activated, T cells downregulate lymph node retention signals and upregulate receptors that facilitate their exit from the lymph node via efferent lymphatic vessels. This process returns them to the bloodstream, from where they can circulate and home to sites of inflammation or tumor growth.

Step 2. Homing to the Tumor Microenvironment. Killer T cells in the bloodstream are guided to tumor sites by a combination of adhesion molecules and chemokine gradients expressed by the tumor vasculature and stroma. The multistep process of T cell extravasation into tumors includes:

  • Tethering and Rolling: T cells slow down as they encounter the tumor endothelium.
  • Chemokine Signaling: Chemokines produced in the tumor microenvironment bind to their receptors on T cells.
  • Firm Adhesion: Activated molecules on T cells bind to their ligands on endothelial cells, anchoring the T cell.
  • Transmigration: T cells then migrate through the endothelial barrier into the tumor tissue.

6. Tumor Recognition and Killing

Inside the tumor, T cells face many obstacles before they reach cancer cells. Killer T cells recognize cancer markers and release chemicals to kill the tumor cells. These chemicals make holes in cancer cells, causing them to die.

  • Once within the tumor, T cells must navigate the dense extracellular matrix and immunosuppressive microenvironment. The efficiency of T cell infiltration can be influenced by the presence of physical barriers, chemokine mismatches, and tumor-derived suppressive factors.
  • One mechanism of killing is direct cytotoxicity via granzymes and perforin. Perforin forms pores in the tumor cell membrane, allowing granzymes to enter and induce programmed cell death (apoptosis). Killer T cells recognize tumor-specific antigens presented by major histocompatibility complex class molecules on the surface of tumor cells. Upon recognition, they release preformed cytotoxic granules containing perforin and granzymes.

 Conclusions

Tumor antigens reach lymph nodes by immune cells or direct flow. Dendritic cells are the main cells that show tumor parts to T cells. T cells need several signals to attack tumors, leave lymph nodes, and enter tumors in a careful process

  • Tumor antigens reach the lymph node via dendritic cell migration or direct lymphatic drainage.
  • Dendritic cells are the primary presenters of tumor antigens to T cells.
  • Effective generation of tumor-specific killer T cells requires antigen presentation, and other signals within the lymph node.
  • Activated T cells exit the lymph node to mediate antitumor effects and establish immune memory.
  • T cell trafficking from lymph nodes to tumors is a highly regulated, multistep process involving antigen priming, changes in homing receptor expression, egress from lymph nodes, navigation through the bloodstream, and infiltration into the tumor microenvironment.

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

 

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)